FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(2 sites)
United States
Yale University, New Haven, Connecticut The Ohio State University Comprehensive Cancer Center, Columbus, Ohio Last updated February 2026